Business Context and Reporting Period
This Form 8-K is filed by Cerecor Inc. (not Avalo Therapeutics, Inc.) on November 13, 2018. The filing serves to announce the company's financial results for the third quarter ended September 30, 2018. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided text is a cover document referencing a press release (Exhibit 99.1) for detailed figures. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for specific financial data.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. It solely indicates that results for the third quarter of 2018 have been issued.
Guidance, Outlook, and Risks
The document includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are detailed within the text of this 8-K form itself.
Investor Verification Checklist
- Verify the correct registrant name is Cerecor Inc., as the input metadata incorrectly listed Avalo Therapeutics, Inc.
- Review Exhibit 99.1 (the press release) to obtain actual revenue, net loss, and cash position figures for Q3 2018.
- Confirm the company's status as an Emerging Growth Company and its election to use the extended transition period for accounting standards.
- Note that the financial data in this filing is not legally "filed" for liability purposes under Section 18 of the Exchange Act.